Cargando…
Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung
BACKGROUND: Despite approvals of immune checkpoint inhibitors in both small cell and non-small cell lung cancers, the role of immunotherapy in large cell neuroendocrine carcinoma (LCNEC) in lung is undefined. METHODS: Using the National Cancer Database (NCDB), Stage IV lung LCNEC cases diagnosed fro...
Autores principales: | Komiya, Takefumi, Ravindra, Neema, Powell, Emily |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190341/ https://www.ncbi.nlm.nih.gov/pubmed/33639649 http://dx.doi.org/10.31557/APJCP.2021.22.2.365 |
Ejemplares similares
-
Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer
por: Komiya, Takefumi, et al.
Publicado: (2023) -
A Rare Presentation of Stage IV Large Cell Neuroendocrine Carcinoma of the Cervix with Metastasis to the Cranium
por: Hooker, Neema, et al.
Publicado: (2018) -
Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2020) -
Recent trends in use of adjuvant chemotherapy in elderly stage II–III non-small cell lung cancer
por: Komiya, Takefumi, et al.
Publicado: (2020) -
Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I–IV Stage
por: Lowczak, Anna, et al.
Publicado: (2021)